CASE REPORT

A coexistence of pemphigus vulgaris and type II diabetes in geriatric patient: a case report

Nyoman Suryawati , I Gusti Ayu Agung Praharsini, Made Wardhana, I Gusti Nyoman Darmaputra

Nyoman Suryawati
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia. Email: [email protected]

I Gusti Ayu Agung Praharsini
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia

Made Wardhana
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia

I Gusti Nyoman Darmaputra
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia
Online First: April 01, 2020 | Cite this Article
Suryawati, N., Praharsini, I., Wardhana, M., Darmaputra, I. 2020. A coexistence of pemphigus vulgaris and type II diabetes in geriatric patient: a case report. Bali Medical Journal 9(1): 314-317. DOI:10.15562/bmj.v9i1.1643


Background: Pemphigus Vulgaris (PV) is an autoimmune bullous disorder that usually affected the middle-aged and elderly. PV management in elderly patients is still a challenge for clinicians because of an increased risk of developing diabetes in the elderly. Corticosteroid is the first-line treatment for PV; however, careful consideration should be taken for diabetes patients due to the risk of disrupting glucose control leading to acute decompensation.

Case: A seventy-year-old female with type II diabetes reported to Sanglah General Hospital with multiple painful blisters on the chest, back, and oral mucous. She has been treated with insulin since last year, but the treatment was non-compliant. Dermatological examination showed multiple flaccid bullae containing serous fluid with a positive Nikolsky sign, and multiple skin erosions. Histopathology finding is appropriate with PV. The Tzank smear examination revealed acantholytic cells. She was diagnosed with PV and typed II diabetes; therefore, we treated her with azathioprine, insulin and Lantus injection; sodium chloride 0.9% compress and fusidic acid cream 2% twice daily for topical treatment.

Conclusion: Azathioprine is the treatment of choice because it works by blocking DNA replication without increasing blood glucose levels. The selection of appropriate medications can improve patient prognosis.

References

Handa H. A Comprehensive Review on Pemphigus Vulgaris. Biomedical Journal of Scientific & Technical Research. 2017;1:1796–9.

Dimarco C. Pemphigus: Pathogenesis to Treatment. Rhode Island Medical Journal. 2016;28:28–31.

Weyand CM, Goronzy JJ. Aging of the Immune System. Mechanisms and Therapeutic Targets. Annals of the American Thoracic Society. 2016 Dec;13(Supplement_5):S422–8.

Ponnappan S, Ponnappan U. Aging and Immune Function: Molecular Mechanisms to Interventions. Antioxidant and Redox Signaling. 2011;8:1551–85.

Castelo-Branco C, Soveral I. The immune system and aging: a review. Gynecological Endocrinology. 2014;30(1):16–22.

Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. British Journal of Dermatology. 2017;177(5):1170–201.

Jannot-Lamotte M, Raccah D. Management of diabetes during corticosteroid therapy. Presse Med. 2000;29:263–6.

Sanders WJ. A brief review of pemphigus vulgaris. Biomedical Dermatology. 2017;1:1–7.

Payne A, Stanley J. Pemphigus. In: Kang S, Amagai M, Bruckner A, Enk A, Margolis D, McMichael A, et al., editors. Fitzpatrick’s Dermatology. Ninth. New York: Mc Graw Hill Education; 2019. p. 909–33.

Wojnarowska F, Venning V. Immunobullous Diseases. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rooks’s Textbook of Dermatology. Eight. Wiley-Blackwell; 2010. p. 40.1-40.23.

Ganapathy S, Vedam V, Rajeev V, Arunachalam R. Autoimmune Disorders – Immunopathogenesis and Potential Therapies. Journal of Young Pharmacists. 2017 Jan 10;9(1):14–22.

Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proceedings of the Royal Society B: Biological Sciences. 2015 22;282(1821):20143085.

Fuentes E, Fuentes M, Alarcón M, Palomo I. Immune System Dysfunction in the Elderly. Anais da Academia Brasileira de Ciências. 2017;89(1):285–99.

Ozougwu O. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. Journal of Physiology and Pathophysiology. 2013;4(4):46–57.

Lee PG, Halter JB. The Pathophysiology of Hyperglycemia in Older Adults: Clinical Considerations. Diabetes Care. 2017;40(4):444–52.

Habib G, Dar-Esaif Y, Bishara H, Artul S, Badarny S, Chernin M, et al. The impact of corticosteroid treatment on hemoglobin A1C levels among patients with type-2 diabetes with chronic obstructive pulmonary disease exacerbation. Respiratory Medicine. 2014;108(11):1641–6.

Simmons LR, Molyneaux L, Yue DK, Chua EL. Steroid-Induced Diabetes: Is It Just Unmasking of Type 2 Diabetes? ISRN Endocrinology. 2012;2012:1–5.

Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clinics in Dermatology. 2012;30(1):78–83.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0